Objectives: This meta-analysis investigates the prognostic effect of SET binding protein 1 (SETBP1) mutations in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or chronic neutrophilic leukemia (CNL).
Methods: Eligible studies from Pubmed, Embase, and Web of Science were searched from database inception through April 2016. Hazard ratios (HRs) and 95% confidence interval (CI) of overall survival (OS) were pooled to calculate the prognostic significance of SETBP1 mutation in patients.
Results: A total of 12 studies with 2321 patients were included in this meta-analysis; 4 studies for MDS, 5 studies for CMML, and 3 studies for CNL. Pooled results suggested that MDS and CMML patients with SETBP1 mutations had a significantly poorer prognosis when compared with patients with wild-type SETBP1 (MDS: HR = 1.808, 95% CI (1.218-2.685), P = 0.001; CMML: HR = 2.223, 95% CI (1.493-3.308), P<0.001). SETBP1 mutations in CNL patients however, showed no significant effect on the overall survival (HR = 1.773, 95% CI (0.877-3.582), P = 0.111). The Begg's and Egger's tests did not show significant publication bias in any groups.
Conclusions: Current evidence shows that SETBP1 mutation is associated with a poor prognosis in patients with MDS and CMML, but not in patients with CNL.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5291491 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0171608 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Managing High-Risk PTPN11-Mutated Juvenile Myelomonocytic Leukemia in a Patient with SETBP1 Mosaicism.
Pediatr Blood Cancer
December 2024
Pediatric Hematology-Oncology Department, University Children's Hospital of Basel, Basel, Switzerland.
Classification and Prognostic Stratification Based on Genomic Features in Myelodysplastic and Myeloproliferative Neoplasm- and Their Overlapping Conditions.
Cancers (Basel)
December 2024
Department of Laboratory Medicine, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
: Myeloid neoplasms encompass a diverse group of disorders. In this study, we aimed to analyze the clinical and genomic data of patients with myeloproliferative neoplasm (MPN), myelodysplastic neoplasm (MDS), and their overlapping conditions, such as MDS/MPN and aplastic anemia (AA), to help redefine the disease classification. : Clinico-genomic data of 1585 patients diagnosed with MPN ( = 715), MDS ( = 698), MDS/MPN ( = 78), and AA ( = 94) were collected.
View Article and Find Full Text PDFClinical outcomes of patients diagnosed with mutated myeloid neoplasms.
Leuk Lymphoma
November 2024
Division of Hematology, Mayo Clinic, Rochester, MN, USA.
SETBP1 mutations (m) have been previously reported in myeloid neoplasms and are associated with poor prognostic co-mutations and cytogenetic abnormalities. We retrospectively analyzed the charts of 113 patients diagnosed with myeloid neoplasms with SETBP1m. The most common diagnosis was MDS (31%).
View Article and Find Full Text PDFPrognostic impact of next-generation sequencing on myelodysplastic syndrome: A single-center experience.
Medicine (Baltimore)
October 2024
Hematology Department, İzmir City Hospital, Bayrakli/İzmir, Turkey.
Article Synopsis
- * Recent studies utilizing next-generation sequencing (NGS) have identified numerous genetic abnormalities in patients with MDS, revealing mutations in 21 different genes that could correlate with disease characteristics and clinical outcomes.
- * Findings suggest that certain non-SF3B1 mutations are associated with worse clinical indicators, such as thrombocytopenia and decreased overall survival, indicating that NGS could play a crucial role in future prognostics for MDS, even in patients with normal cytogenetics.
Whole‑exome sequencing insights into synchronous bilateral breast cancer with discordant molecular subtypes.
Oncol Lett
December 2024
Department of Pathology, The First Affiliated Hospital of Dali University, Dali, Yunnan 671000, P.R. China.
The incidence of synchronous bilateral breast cancer (SBBC) is very low, and SBBC with discordant molecular subtypes is even more uncommon. As such, little is known about the pathogenesis of SBBC with discordant molecular subtypes, and reports about this entity are scarce. In the present study, the case of a 72-year-old female patient who presented with SBBC with discordant molecular subtypes is reported, with a stage IA hormone receptor negative {human epidermal growth factor receptor-2 [HER2(+)]} tumor in the left breast and a stage IIIA hormone sensitive tumor [HER2(-)] in the right breast.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!